Therefore, considering the therapeutic potential of PARP inhibitors in the treatment of oral cancer, the current study suggested that combination of cisplatin and AZD2281 is one of the promising candidates for treatment strategy. Here, PARP1 is linked to lip and oral cavity carcinoma.